Sign in

You're signed outSign in or to get full access.

Jeffrey D. Cunningham

Senior Vice President and Chief Technology Officer at HEALTHSTREAM
Executive

About Jeffrey D. Cunningham

Senior Vice President and Chief Technology Officer at HealthStream (HSTM); joined in July 2017 after founding and serving as CTO and Chief Strategy Officer at Informatics Corporation of America for 12 years. He holds a B.S. in Computer Science from the University of North Texas; age 57 as disclosed in 2024 executive officer table . Company performance metrics tied to executive incentives emphasize Adjusted EBITDA and revenue growth; for 2024 HSTM delivered net income of $20.0M and Adjusted EBITDA of $66.7M, with pay-versus-performance TSR value of $117.87 based on a $100 initial investment framework .

Past Roles

OrganizationRoleYearsStrategic Impact
Informatics Corporation of AmericaFounder; Chief Technology Officer; Chief Strategy Officer12 yearsLed technology and strategy at a healthcare informatics company; prior experience cited by HSTM in executive biography

Fixed Compensation

  • Cunningham is not a Named Executive Officer (NEO) in recent proxies; individual base salary, target bonus, and actual bonus amounts are not disclosed .
  • Plan design applicable to NEOs and “certain other vice presidents and management level employees” for 2024: cash bonus funded by Adjusted EBITDA with target payout at 35–40% of base salary (NEO-specific) and a stretch payout tied to revenue growth; details below. Cunningham’s specific target/payouts are not individually disclosed .

Performance Compensation

MetricTarget/ThresholdActual (2024)Payout OutcomeVesting / Notes
Adjusted EBITDA (Cash Incentive Plan)Threshold: $63.0M; Target: $66.0M$66.7M (after minor acquisition adjustment)Target bonus levels funded for eligible participants; no stretch without revenue growth trigger
Revenue Growth Percentage (Stretch)Stretch thresholds: 6% → +10% of base; 7% → +15%; 8% → +20%<6% (2024 Incentive Plan Revenue $291.5M)0% stretch payout for 2024Stretch only available if EBITDA target met; revenue excludes impact of 2024 acquisitions/divestitures
  • Time-based RSUs: HSTM uses semi-annual grants (March/September) with vesting in increasing annual tranches of 15%, 20%, 30%, 35%, supporting retention via staggered vest dates .
  • Performance-based RSUs (plan-level design): multi-year awards vest in five installments (15%, 20%, 20%, 20%, 25%) contingent on annual performance targets (e.g., adjusted EBITDA/revenue thresholds) over 5-year horizons; award specifics are disclosed for certain NEOs, but not for Cunningham .

Company Performance (Pay vs Performance Context)

Metric20202021202220232024
Net Income ($USD)$14,091,000 $5,845,000 $12,091,000 $15,213,000 $20,007,000
Adjusted EBITDA ($USD)$49,248,000 $52,315,000 $53,192,000 $61,295,000 $66,726,000
TSR (Value of $100 Investment)80.29 96.91 91.32 99.78 117.87

Equity Ownership & Alignment

  • Beneficial ownership: recent proxies list individual holdings for directors and NEOs; Cunningham is not individually enumerated, implying his holdings are only reflected within the “all directors and executive officers as a group” total and not separately disclosed .
  • Insider trading policy includes an anti-hedging prohibition for directors, executive officers, and key employees; pledging prohibitions are not explicitly disclosed in the proxy .
  • Clawback policy: mandatory recovery of erroneously awarded incentive-based compensation under SEC/Nasdaq rules (10D-1/Nasdaq 5608); applies to current and former executive officers .
  • Equity award mechanics: under the 2016/2022 plans, time-based RSUs and stock options fully vest upon a change-in-control; performance-based RSUs vest for the current and next performance periods (and for a just-ended year prior to the next vest date) subject to Compensation Committee determinations .

Employment Terms

  • No employment, severance, or change-in-control agreements are maintained for executive officers other than the CEO; accordingly, Cunningham has no individual severance/change-in-control agreement disclosed. Equity awards’ CIC treatment follows plan terms as noted above .
  • Non-compete/non-solicit terms are disclosed solely for the CEO’s agreement; no separate post-termination covenants are disclosed for Cunningham .

External Roles

  • No public company directorships or outside board roles for Cunningham are disclosed in the proxy .

Risk Indicators & Red Flags

  • Related-party transactions: none requiring disclosure since Jan 1, 2024 (applies company-wide) .
  • Section 16(a) compliance: company states required insider filings were timely in 2024 except two instances unrelated to Cunningham; individual Form 4 activity for Cunningham is not provided in the proxy, limiting visibility on potential selling pressure .
  • Say-on-pay: strong shareholder support (approval ~96% in 2024; ~94% in 2023), indicating broad endorsement of compensation framework .
  • Peer benchmarking: Compensation Committee applies a “market check” but does not target/benchmark to a specific percentile, reducing pay ratcheting risk from peer-group inflation .

Investment Implications

  • Alignment: Cunningham’s incentives are linked to company-level Adjusted EBITDA and revenue growth through the annual cash plan and equity programs; the 2024 outcome funded target bonuses while eliminating stretch payouts due to sub-6% revenue growth—consistent with pay-for-performance discipline .
  • Retention risk: Absence of individual severance/CIC agreements (outside equity plan terms) suggests retention hinges on ongoing RSU vesting and role-based progression; semi-annual RSU grants with 4-year rising vest tranches create recurring vest events that may coincide with liquidity windows, but individual Form 4 activity for Cunningham is not disclosed in the proxy .
  • Governance and clawback: Anti-hedging and mandatory clawback policies reduce misalignment/recourse risk; no explicit pledging prohibition disclosed—monitor for any future policy changes or executive pledging disclosures .
  • Execution context: Company performance trends (Adjusted EBITDA +9% YoY to $66.7M in 2024; net income $20.0M; TSR improvement vs 2019 baseline) support the incentive framework tied to operational outcomes; continued delivery on EBITDA and revenue growth will be key to future vesting/payouts and retention of technology leadership .